The Irish company Endo International announced that it would acquire Par Pharmaceutical for $8.05 billion.

AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.

UK-based Circassia invests approximately $377 million on Aerocrine and Prosonix, two companies focused on asthma.

CPhI Worldwide announces the 2015 Expert Panel, including 2014 panel veterans and three new members.

Raplixa fibrin sealant, the first approved spray-dried biologic, is a hemostatic agent that helps control bleeding from small blood vessels during surgery.

SAFC’s new ADC wing in St. Louis, MO will feature commercial-scale manufacture of antibody-drug conjugates, and its Carlsbad, CA site will offer enhanced gene-therapy services.

The dinner will be held on Oct. 14, 2015 during CPhI Worldwide, at the Prado Museum in Madrid.

Supply chain consortium establishes a working group to address quality problems in India.

CPhI Istanbul to feature materials, manufacturing, packaging and contract services solutions.

Pall has agreed to be acquired by Danaher for $127.20 per share.

Eli Lilly announces that it will establish a drug delivery and device center in Cambridge, Massachusetts.

Juno Therapeutics announces that it will expand its cellular therapies pipeline with the acquisition of Stage Cell Therapeutics for €52.5 million.

Pluristem Therapeutics announces that Japan’s Pharmaceuticals and Medical Devices Agency agreed with its methods for the manufacture of PLX-PAD cells.

Pfizer acquires minority equity stake in AM-Pharma and secures option to acquire remaining equity.

With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.

CombiLac is a lactose-based, co-processed excipient, designed to ease oral solid dosage form development and manufacture in direct compression.

The new Kaye Validator AVS combines accurate sensor measurements with all GMP requirements for calibration and traceability.

Turkey continues to dominate the MENA pharma region as regional manufactures expand at double-digit pace with the arrival of international players.

The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.

A vaccine patch may eliminate the need for traditional means of vaccine distribution, according to an article in NPR.

FDA issues a Form 483 following inspection of Impax Laboratories' Hayward, CA facility.

The basic principle behind QbD is that quality should be built into a product with an understanding of the product and process by which it is developed and manufactured along with a knowledge of the risks involved in manufacturing the product and how best to mitigate those risks.

Novartis announces that its lung cancer drug, Zykadia, gained European Union approval.

A range of packages is available for industry partners to implement charity giving.

Johnson & Johnson announces partnership with NYU School of Medicine to launch a compassionate care committee for individual patient requests of investigational drugs.

BASF announces that it will sell its custom synthesis business and parts of its API business to focus its expertise on pharmaceutical excipients.

The US Court of Appeals granted Amgen’s request to block Novartis’ Neupogen biosimilar, Zarxio, from the US market until the court resolves litigation between the two companies.

Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.